LBA51 IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma

作者：Peter R. Galle, Jordi Bruix, Roman Kloeckner, Jörg Trojan, Thomas J. Vogl, T.T. Lüdde, P. Lampertico, Jean‐Charles Nault, M. Bouattour, T.O. Goetze, P. Merle, A. Saborowski, M. Peck Radosavljevic, Vikas Ostwal, Matthias Pinter, A. Auriemma, M. Kudo, M.E. Reig Monzon, S-E. Al-Batran, Friedrich Foerster · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.09.063 · 被引用次数：4 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver physiology and pathology、Peptidase Inhibition and Analysis